Arcus Biosciences and Infinity Pharmaceuticals have entered into a clinical collaboration to evaluate two triple combination therapies in certain tumor types which typically show minimal response to checkpoint inhibition monotherapy.
Synairgen said that its antiviral therapy SNG001 has so far registered positive safety data in an ongoing phase 2 trial in patients with chronic obstructive pulmonary disease (COPD).
A clinical trial, funded by Cancer Research UK, has shown that administering sodium thiosulphate (STS) after chemotherapy ‘cisplatin’ for the treatment of childhood liver cancer hepatoblastoma reduces hearing loss in children by almost 50%.
Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.
Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated.
Bristol-Myers Squibb (BMS) has announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint.
Israel-based Teva Pharmaceutical Industries said that it will stop an ongoing phase 3 trial of its migraine drug fremanezumab for the treatment of chronic cluster headache due to futility.
Faron Pharmaceuticals has announced preliminary biomarker data from its Phase III INTEREST trial of Traumakine for the treatment of Acute Respiratory Distress Syndrome (ARDS).
ViiV Healthcare reported that two phase 3 trials evaluating the two-drug regimen (2DR) of dolutegravir (Tivicay) and lamivudine (Epivir) in treatment naïve HIV-1 infected adults demonstrated the ability to control HIV.
Flex Pharma said that it is scrapping two ongoing phase 2 neuromuscular disease trials, evaluating its lead drug candidate FLX-787, due to safety concerns.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.